Atherosclerotic cardiovascular disease risk

1. Fibrinogen is linked with atherosclerotic cardiovascular disease risk in humans.

   “Path analysis revealed a mediating role of fibrinogen in the inflammation [i.e. interleukin-6 (IL-6)]-ASCVD risk association”

   Humansinterleukin-6-associated inflammation; mediation more pronounced at higher lipoprotein(a) concentrations20 years

   The interplay of fibrinogen and lipoprotein(a) with 20-year atherosclerotic cardiovascular disease risk: a path analysis within the ATTICA study (2002-2022)

   European journal of preventive cardiology·Nov 3, 2026

More on Fibrinogen

1. achieved BMI <25 kg/m2 decreases atherosclerotic cardiovascular disease risk in humans (39.4% vs 10.6% mean percent risk reduction).

   “Mean percent risk reduction from baseline to trial end was significantly greater for those with BMI <25 kg/m2 (39.4%) than those with BMI ≥25 kg/m2 at trial end (10.6%; p<.001).”

   Human trialparticipants with obesity/overweight randomized to tirzepatide or placebo, pooled SURMOUNT-1, -3 and -CNto trial end (52 or 72 weeks)

   Achieving BMI <25 kg/m2 Was Associated with Reduced Predicted Risk of Atherosclerotic Cardiovascular Disease in People with Obesity or Overweight—A Post Hoc Analysis of SURMOUNT-1, -3, and -CN

   ADA Scientific Sessions 2025 abstract·Jun 13, 2025

1. Age increases atherosclerotic cardiovascular disease risk in humans.

   “Because ASCVD risk increases with age”

   Review

   Drug Therapy of Dyslipidemia in the Elderly

   Drugs & aging·Apr 1, 2019

1. HDL cholesterol is associated with atherosclerotic cardiovascular disease risk (Epidemiological association; causal connection not confirmed).

   “the epidemiological evidence of a potent inverse relation between HDL-C and ASCVD risk”

   ReviewEpidemiological association; causal connection not confirmed

   HDL and apoB: physiological and pathophysiological intersections and interactions

   Current opinion in cardiology·Nov 6, 2026

More on HDL cholesterol

1. multimodal Transformer predicts atherosclerotic cardiovascular disease risk in silico.

   “The Transformer also achieved strong performance for ASCVD and stroke prediction.”

   In silico

   AI model outperformed heart disease risk tools in US records

   AHA Scientific Sessions 2026 abstract·Nov 2, 2026

1. PREVENT predicts atherosclerotic cardiovascular disease risk in humans (older adults without CVD) (C statistic 0.793 vs 0.740, P<0.001).

   “PREVENT showed superior discriminative performance compared with PCE (PREVENT versus PCE, C statistic, 0.793 versus 0.740; P<0.001 in participants aged 65 -79 years”

   Humansolder adults without CVDn = 15,510

   Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults

   Circulation. Cardiovascular quality and outcomes·Apr 28, 2025

More on PREVENT